Delivery Order SPE2DB20D7059-SPE2DB25FQJV3
- Not listed
- The Defense Logistics Agency awarded a $5,189.99 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Dupixent 200 mg/1.14 ml syringes on July 14, 2025, with an ultimate completion date of July 15, 2025. This non-set-aside contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999.99 million and extending through December 2026. The place of performance is AmerisourceBergen's...
- The Defense Logistics Agency awarded a $31,152.11 delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Dupixent 200 mg/1.14 mL syringes with a completion date of August 5, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The product will be delivered to AmerisourceBergen's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Dupixent 300 mg/2 ml syringes with a contract value of $42,767.05. This non-set-aside, firm fixed-price delivery order is scheduled for completion by August 26, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $69,305.82 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml syringes on May 27, 2025, with completion scheduled for May 28, 2025. This firm fixed price contract represents a non-competitive set-aside and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication commonly prescribed for severe asthma, eczema, and other inflammatory conditions, making this delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $3,831.09 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml syringes on October 27, 2025, with completion expected by October 28, 2025. This firm fixed-price delivery order represents a non-competitive, non-set-aside award issued under AmerisourceBergen's existing contract vehicle with DLA. The pharmaceutical product will be delivered to the company's headquarters location in Conshohocken, Pennsylvania. Dupixent is a...
- The Defense Logistics Agency awarded a $13,593.94 delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Dupixent 300 mg/2 mL syringes. This firm fixed-price, non-set-aside contract is classified as a delivery order with an ultimate completion date of September 18, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication primarily used to treat moderate-to-severe...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $26,522.23 for Dupixent (dupilumab) 300 mg/2 mL syringes on August 26, 2025, with an ultimate completion date of August 27, 2025. This firm fixed-price, competitively awarded contract involves no set-aside designation and is being performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $23,017.37 firm fixed price delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL syringes on September 15, 2025, with completion targeted for September 16, 2025. This non-set-aside competitive award represents a single delivery order under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The product will be delivered...
- The Defense Logistics Agency awarded a $14,845.54 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml syringes on July 23, 2025, with completion scheduled for July 24, 2025. This competitively awarded, firm fixed price contract contains no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication primarily used to treat moderate-to-severe atopic dermatitis,...
- The Defense Logistics Agency awarded a $20,624.88 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of Dupixent 300 mg/2 ml syringes. This non-set-aside contract, which is a child order under a larger indefinite delivery contract vehicle, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of September 23, 2025. Dupixent is a biologic medication commonly prescribed...
- SPE2DB20D7059Indefinite Delivery Contract
- SPE2DB20D7059-SPE2DB25FQJV3Delivery Order
The Defense Logistics Agency awarded a $3,418.92 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml syringes on June 16, 2025, with an ultimate completion date of June 17, 2025. This non-set-aside contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and running through December 2026. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent is a prescription biologic medication used to treat conditions such as atopic dermatitis, eosinophilic esophagitis, and moderate-to-severe asthma, and this order supports federal medical supply requirements for military and veteran healthcare systems. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement through its comprehensive IDC with DLA. The company maintains extensive capability to supply brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. This delivery order exemplifies AmerisourceBergen's role in fulfilling DLA's pharmaceutical supply needs through competitive, firm fixed-price transactions ranging from small-value orders to substantial procurements, supporting the Defense Health Agency and other federal healthcare systems worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.4k | 6/16/25 |